Skip to content
Medical Health Aged Care

Notice Concerning Change of Representative Executive Officer

Fujirebio 2 mins read
TOKYO--BUSINESS WIRE--

H.U. Group Holdings, Inc. (the Company) today announced that it has resolved, at a meeting of the Board of Directors held on January 14, 2026, to change the Company’s Representative Executive Officer as described below.

1. Name and job titles of newly appointed Representative Executive Officer

Name

New title

Current title

Goki Ishikawa

Representative Executive Officer,
President and Group CEO

Managing Executive Officer

2. Name and job titles of retiring Representative Executive Officer

Name

New title

Current title

Shigekazu Takeuchi

Director and Executive Officer

Director, Representative Executive Officer, Chairman, President and Group CEO

3. Reason for change

In May 2025, toward realizing its Vision for 2035, the Company announced its Medium-Term Management Plan “H.U. 2030” (MMP) as well as its CEO succession plan including the timing for the selection of the next CEO. As the succession plan progressed, the Company has recognized that Mr. Goki Ishikawa is the best to lead the execution of MMP as CEO considering he has made significant contributions to the growth of the H.U. Group as an Executive Officer in charge of IVD, which led to the resolution.

4. Career summary of newly appointed Representative Executive Officer

Name : Goki Ishikawa
Date of birth : November 18, 1976
Number of shares held : 20,100 shares (As of June 2025)

Career summary :

Mar. 1999

University of Tokyo, B.A. Economics

Apr. 2000

Joined the Japan Defense Agency (currently Ministry of Defense, Japan)

Jun. 2006

Harvard Business School, M.B.A.

Sep. 2006

Joined the Boston Consulting Group

Dec. 2008

Joined Elsevier

Jan. 2012

Joined the Company

Jun. 2013

Director, Fujirebio Diagnostics Inc. (incumbent)

Apr. 2014

Director, FUJIREBIO INC.

Jun. 2014

Director, Fujirebio Europe N.V. (incumbent)

Mar. 2015

Representative Director, FUJIREBIO INC.

Apr. 2016

Representative Managing Director, FUJIREBIO INC.

Apr. 2017

Executive Vice President & Representative Director, FUJIREBIO INC.

Executive Vice President & Representative Director, Fujirebio Holdings, Inc.

Jun. 2018

President & CEO, FUJIREBIO INC.

Jun. 2020

Executive Officer of the Company

President & CEO, Fujirebio Holdings, Inc. (incumbent)

Director, FUJIREBIO INC. (incumbent)

Jun. 2023

Director, SRL, Inc. (incumbent)

Jun. 2025

Managing Executive Officer of the Company (incumbent)

5. Scheduled date of assuming office

April 1st, 2026


Contact details:

For media:
Public Relations Section, Public Relations/Sustainability Dept.
Phone: +81-3-6279-0884
Email: [email protected]

For investors and analysts:
IR/SR Dept.
Phone: +81-3-6279-0926
Email: [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 14/01/2026
  • 17:11
Galderma

TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics

Galderma will present data on Relfydess® (RelabotulinumtoxinA) – the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology – which further demonstrate its…

  • Contains:
  • Medical Health Aged Care
  • 14/01/2026
  • 08:57
Neuroscience Research Australia (NeuRA)

Graded sensorimotor retraining shows similar benefits to all people with chronic low back pain

Researchers have found the benefits of graded sensorimotor retraining for people with chronic low back pain are likely to be similar across a range of people, rather than being limited to specific subgroups. Low back pain affected 619 million people worldwide in 2020 and contributes the largest share of the disability burden. The research investigated whether eight clinical and psychological variables modify the effect of treatment on pain intensity and disability levels. New research has found that the benefits of graded sensorimotor retraining are likely to be similar for all patients with chronic low back pain. Low back pain is…

  • Medical Health Aged Care
  • 13/01/2026
  • 22:11
BeOne Medicines Ltd.

BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J.P. Morgan Healthcare Conference

Company outlines foundational hematology leadership, multiple 2026 data catalysts, a unique global clinical development superhighway, and continued financial excellence SAN CARLOS, Calif.–BUSINESS WIRE– BeOne…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.